Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (PGNY) generates a steady flow of news as a global leader in women’s health and family building solutions listed on the Nasdaq Global Select Market. Company updates frequently focus on fertility and women’s health benefits, research on employee and member needs, and financial performance, giving investors and benefits professionals insight into how Progyny’s model is evolving.
News coverage commonly includes quarterly earnings results and financial guidance, which are also referenced in the company’s Form 8-K filings. These releases discuss revenue from fertility benefit services and pharmacy benefit services, member engagement trends, client additions, and key metrics such as assisted reproductive treatment cycles and utilization rates. Investors following PGNY news can see how changes in client count, covered lives, and engagement influence the company’s reported results and outlook.
Progyny also issues news about new programs and product expansions. For example, it has announced pregnancy, postpartum, and menopause programs for global employers that complement its existing global fertility and family building offering, along with details on features such as Global Care Advocates, knowledge centers, and country-specific navigator support. These announcements provide context on how Progyny is extending its reach across the women’s health continuum and into global markets.
Another important category of news involves research and thought leadership. Progyny has released studies on men’s fertility experiences and on gaps between employee expectations and employer offerings in women’s health benefits, conducted with Dynata. These stories highlight barriers such as stigma, cost, and benefit complexity, and they underscore the company’s focus on data-driven insights for employers.
Additional news items may cover conference participation, leadership recognition, and partnerships, such as appearances at healthcare conferences and recognition of the CEO as a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health. For anyone tracking PGNY, this news page offers a centralized view of operational, financial, and strategic developments over time.
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced its executives will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 11:40 A.M. ET. The event will provide insights into their comprehensive fertility solutions aimed at improving patient care and reducing costs for employers. A live audiocast and replay will be available on Progyny's website. The company is noted for its innovative approach and recognition from various organizations, indicating its growth and leadership in the industry.
Progyny, Inc. (Nasdaq: PGNY) will release its financial results for Q1 2022 on May 5, 2022, after market close. A conference call will follow at 4:45 PM Eastern Time. Interested parties can join via phone or through a live webcast available on the company’s investor relations page. Progyny specializes in fertility benefits management, offering comprehensive solutions that enhance patient care while reducing employer healthcare costs. The company has gained recognition for its innovative approach and commitment to improving fertility solutions across the U.S.
Progyny, Inc. (PGNY) and RESOLVE: The National Infertility Association are set to highlight National Infertility Awareness Week 2022 by ringing the Nasdaq Opening Bell on April 26, 2022, and lighting the Empire State Building in orange on April 27, 2022. This initiative aims to raise awareness about infertility, affecting 1 in 8 couples in the U.S. CEO Pete Anevski emphasized Progyny's mission to support over 100,000 individuals in their family building journeys. The event seeks to eliminate stigmas associated with infertility and calls on employers and legislators to address the crisis.
Progyny (Nasdaq: PGNY), a top benefits management company in fertility and family building solutions, announced that CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 3:50 P.M. ET. This event aims to discuss Progyny's innovative approach to fertility benefits, highlighting its comprehensive solutions that benefit employers, patients, and physicians. A live audiocast and replay will be accessible on their official website.
Progyny, Inc. (PGNY) reported record revenues of $500.6 million for 2021, marking a 45% growth year-over-year. The fourth quarter revenue reached $127.6 million, up 27%, driven by a significant increase in clients. Despite the impact of the COVID-19 Omicron variant, the company maintained a high retention rate and successful sales season. However, net income in Q4 decreased to $15.1 million from $39.1 million the previous year, primarily due to a lower tax benefit. Looking ahead, 2022 guidance forecasts revenue of $730 million to $775 million, reflecting 46% to 55% growth.
Progyny, Inc. (Nasdaq: PGNY) will announce its financial results for the quarterly period and full year ending December 31, 2021, on February 28, 2022. A conference call will be held at 4:45 PM ET to discuss the results, with access details provided for U.S. and international participants. An audio replay will be available until March 7, 2022. Progyny specializes in fertility and family building benefits, focusing on education and access to specialists while reducing costs for employers. The company has received recognition for its growth and leadership in the sector.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced its CEO, Pete Anevski, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 A.M. ET. The presentation will be followed by a breakout session featuring President Michael Sturmer and CFO Mark Livingston. A live audiocast and replay will be accessible on Progyny's website. Progyny is recognized for its innovative fertility solutions that benefit patients, employers, and healthcare providers alike.
Progyny (PGNY) reported a strong third quarter of 2021, with revenues of $122.3 million, marking a 24% increase year-over-year. The company added over 85 new clients, resulting in approximately 1.2 million new covered lives. Gross profit rose to $28.5 million with a gross margin of 23.3%, up from 21.1% in the previous year. Net income reached $16.8 million, a significant increase from $4.8 million last year. For 2022, Progyny anticipates revenue growth of about 50%, driven by new client launches.
Progyny, Inc. (Nasdaq: PGNY) is set to release its financial results for the quarter ending September 30, 2021, on November 4, 2021, after market close. A conference call will follow at 4:45 PM ET, during which the company will discuss its results. Participants can join by dialing the provided numbers. An audio replay will be available until November 11, 2021. Progyny specializes in fertility and family-building benefits, focusing on comprehensive solutions that benefit employers, patients, and healthcare providers.
Progyny, a leader in fertility benefits management, announced that CEO David Schlanger and CFO Mark Livingston will participate in a fireside chat at the BofA Global Healthcare Conference on September 15, 2021, at 10:55 A.M. ET. The event will be accessible via a live audiocast on Progyny’s website. Progyny aims to redefine fertility and family building benefits, enhancing access to comprehensive care and reducing healthcare costs for employers. The company has received multiple recognitions for its growth and leadership.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
